# Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

> **NCT03478488** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **3D Medicines (Sichuan) Co., Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Biliary Tract Neoplasms

## Interventions

- **DRUG:** KN035 plus Gemcitabine & oxaliplatin
- **DRUG:** Gemcitabine & oxaliplatin

## Key facts

- **NCT ID:** NCT03478488
- **Lead sponsor:** 3D Medicines (Sichuan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-16
- **Primary completion:** 2024-09-10
- **Final completion:** 2026-12-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03478488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03478488, "Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03478488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*